Marshall Wace participates in Parse Biosciences Series C equity within $50m combined equity and debt package

Marshall Wace was identified as participating equity investor in Parse Biosciences's Series C equity within $50m combined equity and debt package. The broader package combined equity and debt; a separate equity amount was not disclosed. The announcement identifies the financing participants; Marshall Wace’s individual investment amount and current holding are not established.